Therefore, MET activation status appears to be a better biomarker than HGF expression, and clinical trials are needed to evaluate the efficacy and safety of the triple therapy of MET and VEGF inhibition combined with EGFR TKIs in EGFR-mutant lung cancer patients who acquired EGFR-TKI resistance due to MET overactivation. The gene discussed is EGFR; the disease is lung carcinoma.